
Nine patents from the Royal Cornwall Hospitals Trust (RCHT) have contributed to research trialling a new treatment regime which is set to become the standard treatment for cervical cancer.
Following the publication of results from the INTERLACE trial, women diagnosed with cervical cancer following the new pathway, could see an improvement in their outcomes.
The group receiving the trial medication had an additional course of carboplatin and paclitaxel chemotherapy for six weeks, before receiving the standard combination of radiotherapy plus cisplatin and brachytherapy, which is known as chemoradiation.
The control group received the usual treatment of chemoradiation.
Results showed that after five years 73% of women in the trial group had no recurrence or spread of their cancer.
80% of those who received the new treatment were still alive. This compares to the control group where 64 per cent had not seen their cancer return or spread and 72 per cent were alive. The research was carried out over five countries and included 500 patients.
RCHT Interlace research participant, Karen Yeandle said “I found the research experience really gave my confidence a boost at a very difficult and anxious time.
Being assessed weekly by the Oncology and Research teams, and knowing that the state of the art equipment at Treliske Hospital is amongst the best in the world, kept me feeling positive.
The time passed really quickly and I was so pleased when I heard that the treatment had been successful and am delighted that as a result of this trial, not only has my own survival rate increased, but also that of others in the future.
I feel extremely lucky and blessed that I was randomly selected to have been part of a study that should further improve outcomes for patients.”